{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:50:27Z","timestamp":1793227827767,"version":"4.5.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[1997,10,1]],"date-time":"1997-10-01T00:00:00Z","timestamp":875664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1997,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Postmenopausal women with established vertebral osteoporosis were studied for 2 years to determine the terminal elimination half-life and the duration of response to treatment with intravenous alendronate (30 mg) given over 4 days. The urinary excretion of alendronate followed a multiexponential decline. Approximately 50% of the total dose was excreted over the first 5 days, and a further 17% was excreted in the succeeding 6 months. Thereafter, there was a much slower elimination phase with an estimated mean terminal half-life of greater than 10 years (n = 11). Urinary excretion of hydroxyproline and calcium decreased significantly from pretreatment values by day 3, reaching a nadir by 1 week (40% and 67% decrease, respectively). Thereafter, hydroxyproline remained suppressed for the following 2 years. In contrast, urinary calcium excretion returned gradually toward pretreatment values over the first year and during the second year was comparable to pretreatment values. Serum activity of alkaline phosphatase activity decreased over 3 months (23% reduction), increased gradually thereafter, and returned to pretreatment values at month 24. Bone mineral density measured at the spine increased by approximately 5% during the first year and remained significantly higher than pretreatment values at 2 years. We conclude that a short course of high doses of intravenous alendronate is associated with a prolonged skeletal retention of the agent. This open study also suggests that this regimen has a sustained effect on bone turnover persisting for at least 1 year.<\/jats:p>","DOI":"10.1359\/jbmr.1997.12.10.1700","type":"journal-article","created":{"date-parts":[[2006,4,26]],"date-time":"2006-04-26T21:57:19Z","timestamp":1146088639000},"page":"1700-1707","source":"Crossref","is-referenced-by-count":246,"title":["Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal Osteoporosis"],"prefix":"10.1093","volume":"12","author":[{"given":"Sohail A.","family":"Khan","sequence":"first","affiliation":[{"name":"WHO Collaborating Centre for Metabolic Bone Disease, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Kanis","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Metabolic Bone Disease, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Vasikaran","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Metabolic Bone Disease, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. F.","family":"Kline","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Rahway, New Jersey, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. K.","family":"Matuszewski","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Rahway, New Jersey, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene V.","family":"McCloskey","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Metabolic Bone Disease, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique N. C.","family":"Beneton","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Metabolic Bone Disease, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J.","family":"Gertz","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Rahway, New Jersey, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Sciberras","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Rahway, New Jersey, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. D.","family":"Holland","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Rahway, New Jersey, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Orgee","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Metabolic Bone Disease, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian M.","family":"Coombes","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Metabolic Bone Disease, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne R.","family":"Rogers","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Metabolic Bone Disease, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. G.","family":"Porras","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Rahway, New Jersey, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,3]]},"reference":[{"key":"2024020712015425600_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-642-83668-8_1","article-title":"Bisphosphonates: A new class of drugs in diseases of bone and calcium metabolism","volume":"116","author":"Fleisch","year":"1989","journal-title":"Recent Results Cancer Res"},{"key":"2024020712015425600_bib2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF02405012","article-title":"Structure-activity relationships of various bisphosphonates","volume":"35","author":"Shinoda","year":"1983","journal-title":"Calcif Tissue Int"},{"key":"2024020712015425600_bib3","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(80)91496-8","article-title":"Effects of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease","volume":"1","author":"Douglas","year":"1980","journal-title":"Lancet"},{"key":"2024020712015425600_bib4","volume-title":"Pathophysiology and Treatment of Paget's Disease of Bone","author":"Kanis","year":"1991"},{"key":"2024020712015425600_bib5","volume-title":"Osteoporosis, revised Ed","author":"Kanis","year":"1995"},{"key":"2024020712015425600_bib6","volume-title":"Bisphosphonates in bone disease: From the laboratory to the patient","author":"Fleisch","year":"1995","edition":"2nd Ed."},{"key":"2024020712015425600_bib7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1600-0773.1988.tb01843.x","article-title":"A one year follow-up study of the distribution of 14C-clodronate in mice and rats","volume":"62","author":"Monkkonen","year":"1988","journal-title":"Pharmacol Toxicol"},{"key":"2024020712015425600_bib8","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/BF02555856","article-title":"The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases","volume":"49","author":"Daley-Yates","year":"1991","journal-title":"Calcif Tissue Int"},{"key":"2024020712015425600_bib9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/BF03257396","article-title":"Renal and nonrenal clearance of clodronate in patients with malignancy and renal impairment","volume":"7","author":"O'Rourke","year":"1994","journal-title":"Drug Invest"},{"key":"2024020712015425600_bib10","first-page":"294","article-title":"Comparison of the distribution of three bisphosphonates in mice","volume":"65","author":"Monkkonen","year":"1989","journal-title":"Pharmacol Toxicol"},{"key":"2024020712015425600_bib11","first-page":"926","article-title":"Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals","volume":"19","author":"Lin","year":"1991","journal-title":"Drug Metab Dispos"},{"key":"2024020712015425600_bib12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/clpt.1981.135","article-title":"Clodronate kinetics and dynamics","volume":"30","author":"Conrad","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"2024020712015425600_bib13","first-page":"41","volume-title":"Bone Resorption Metastases and Diphosphonates","author":"Powell","year":"1985"},{"key":"2024020712015425600_bib14","first-page":"222","article-title":"Pharmacokinetics of clodronate in patients with metastatic breast cancer","volume":"27","author":"Pentikainen","year":"1989","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2024020712015425600_bib15","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","article-title":"The diagnosis of osteoporosis","volume":"9","author":"Kanis","year":"1994","journal-title":"J Bone Miner Res"},{"key":"2024020712015425600_bib16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/BF01623275","article-title":"The assessment of vertebral deformity: A method for use in population studies and clinical trials","volume":"3","author":"McCloskey","year":"1993","journal-title":"Osteoporos Int"},{"key":"2024020712015425600_bib17","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0378-4347(92)80551-Z","article-title":"Improved determination of the bisphosphonate alendronate in human plasma and urine by automated precolumn derivitization and high-performance liquid chromatography with fluorescence and electrochemical detection","volume":"583","author":"Kline","year":"1992","journal-title":"J Chromatogr"},{"key":"2024020712015425600_bib18","first-page":"347","article-title":"A specific method for the analysis of hydroxyproline in tissues and urine","volume":"228","author":"Udenfriend","year":"1960","journal-title":"Ann Biochem"},{"key":"2024020712015425600_bib19","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/bmj.290.6470.728","article-title":"Measuring serum calcium","volume":"290","author":"Kanis","year":"1985","journal-title":"Br Med J"},{"key":"2024020712015425600_bib20","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/art.1780310909","article-title":"An evaluation of serum osteocalcin in Paget's disease and its response to diphosphonate treatment","volume":"31","author":"Coulton","year":"1988","journal-title":"Arthritis Rheum"},{"key":"2024020712015425600_bib21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1365-2265.1979.tb03068.x","article-title":"Measurement of 1,25-dihydroxycholecalciferol in man by radioimmunoassay","volume":"11","author":"Clemens","year":"1979","journal-title":"Clin Endocrinol"},{"key":"2024020712015425600_bib22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1042\/cs0630145","article-title":"An estimate of the endogenous secretion rate of calcitonin in man","volume":"63","author":"Kanis","year":"1982","journal-title":"Clin Sci"},{"key":"2024020712015425600_bib23","first-page":"473","article-title":"Effect of dose, sex and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats","volume":"20","author":"Lin","year":"1992","journal-title":"Drug Metab Dispos"},{"key":"2024020712015425600_bib24","first-page":"270","article-title":"The whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone diseases","volume":"9","author":"Fogelman","year":"1978","journal-title":"J Nucl Med"},{"key":"2024020712015425600_bib25","first-page":"265","article-title":"Uptake by bone of pyrophosphate, diphosphonate and their technitium derivatives","volume":"54","author":"Bisaz","year":"1978","journal-title":"Clin Sci Mol Med"},{"key":"2024020712015425600_bib26","first-page":"880","article-title":"A comparison of skeletal uptake of three diphosphonates by whole body retention","volume":"22","author":"Fogelman","year":"1981","journal-title":"J Nucl Med"},{"key":"2024020712015425600_bib27","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1172\/JCI115539","article-title":"Bisphosphonate action: Alendronate localisation in rat bone and effects on osteoclast structure","volume":"88","author":"Sato","year":"1991","journal-title":"J Clin Invest"},{"key":"2024020712015425600_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01623652","article-title":"Rationale for the use of alendronate in osteoporosis","volume":"5","author":"Kanis","year":"1995","journal-title":"Osteoporos Int"},{"key":"2024020712015425600_bib29","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/clpt.1982.51","article-title":"Clodronate kinetics and bioavailability","volume":"31","author":"Yakatan","year":"1982","journal-title":"Clin Pharmacol Ther"},{"key":"2024020712015425600_bib30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF01623223","article-title":"Rationale for the use of clodronate in osteoporosis","author":"Kanis","year":"1993","journal-title":"Osteoporos Int"},{"key":"2024020712015425600_bib31","first-page":"273","article-title":"Morphological basis of bone mineral measurements: Transient and steady state effects of treatment in osteoporosis","volume":"4","author":"Parfitt","year":"1980","journal-title":"Miner Electrolyte Metab"},{"key":"2024020712015425600_bib32","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1210\/jcem.80.12.8530584","article-title":"Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate","volume":"80","author":"Landman","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020712015425600_bib33","first-page":"35","article-title":"Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man","author":"McCloskey","year":"1987","journal-title":"Bone"},{"key":"2024020712015425600_bib34","first-page":"928","article-title":"1,25 dihydroxyvitamin D3 increases serum levels of vitamin K-dependent bone protein","volume":"99","author":"Price","year":"1981","journal-title":"J Biol Chem"},{"key":"2024020712015425600_bib35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1042\/bj1830073","article-title":"Increase in alkaline phosphatase activity in calvaria cells cultured with diphosphonates","volume":"183","author":"Felix","year":"1979","journal-title":"J Biochem"},{"key":"2024020712015425600_bib36","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/000456329403100310","article-title":"Intra-individual variation in fasting urinary calcium and hydroxyproline creatinine ratios measured in metabolic bone clinic patients as both outpatients and in patients","volume":"31","author":"Vasikaran","year":"1994","journal-title":"Ann Clin Biochem"},{"key":"2024020712015425600_bib37","first-page":"S281","article-title":"Oral bioavailability and dose proportionality of alendronate (aminohydroxybutylidene bisphosphonate) in postmenopausal women","author":"Gertz","year":"1991","journal-title":"J Bone Miner Res"},{"key":"2024020712015425600_bib38","first-page":"1693","article-title":"Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment","volume":"79","author":"Garnero","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020712015425600_bib39","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","article-title":"Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodelling","volume":"99","author":"Chesnut","year":"1995","journal-title":"Am J Med"},{"key":"2024020712015425600_bib40","first-page":"1399","article-title":"The effect of short-term treatment with alendronate upon vertebral density and biochemical markers of bone remodelling in early postmenopausal women","volume":"76","author":"Harris","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020712015425600_bib41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/8756-3282(91)90049-O","article-title":"Effects of amino-butylidene diphosphonate in hypercalcaemia due to malignancy","volume":"12","author":"Bickerstaff","year":"1991","journal-title":"Bone"},{"key":"2024020712015425600_bib42","first-page":"713","article-title":"Consequence of neoplasia induced bone resorption and the use of clodronate (Review)","volume":"5","author":"Kanis","year":"1994","journal-title":"Int J Oncol"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.1997.12.10.1700","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/12\/10\/1700\/56596249\/5650121019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/12\/10\/1700\/56596249\/5650121019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:54:01Z","timestamp":1710341641000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/12\/10\/1700-1707\/7514277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,10,1]]},"references-count":42,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2009,12,3]]},"published-print":{"date-parts":[[1997,10,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.1997.12.10.1700","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[1997,10,1]]},"published":{"date-parts":[[1997,10,1]]}}}